I. E. Haines, Dose selection in phase I studies: why we should always go for the Most effective, J Clin Oncol, vol.26, issue.21, pp.3650-3652, 2008.

S. Sleijfer and E. Wiemer, Dose selection in phase I studies: why we should always go for the top, J Clin Oncol, vol.26, issue.10, pp.1576-1584, 2008.

S. Postel-vinay, C. Gomez-roca, L. R. Molife, B. Anghan, A. Levy et al., Phase I trials of molecularly targeted agents: should we pay more attention to late toxicities?, J Clin Oncol, vol.29, issue.13, pp.1728-1763, 2011.

J. Verweij, M. L. Disis, and S. A. Cannistra, Phase I studies of drug combinations, J Clin Oncol, vol.28, issue.30, pp.4545-4551, 2010.

E. K. Fromme, K. M. Eilers, M. Mori, Y. Hsieh, and T. M. Beer, How accurate is clinician reporting of chemotherapy adverse effects? A comparison with patientreported symptoms from the quality-of-life questionnaire C30, J Clin Oncol, vol.22, issue.17, pp.3485-90, 2004.

X. Paoletti, L. Tourneau, C. Verweij, J. Siu, L. L. Seymour et al., Defining dose-limiting toxicity for phase 1 trials of molecularly targeted agents: results of a DLT-TARGETT international survey, Eur J Cancer, vol.50, issue.12, pp.2050-2056, 2014.

C. Henon, D. Lissa, X. Paoletti, C. Thibault, T. C. Le et al., Patientreported tolerability of adverse events in phase 1 trials, ESMO Open, vol.2, issue.2, p.148, 2017.

J. Ringash, G. Lockwood, B. O'sullivan, W. P. Bayley, A. Cummings et al., Hyperfractionated, accelerated radiotherapy for locally advanced head and neck cancer: quality of life in a prospective phase I/II trial, Radiother Oncol, vol.87, issue.2, pp.181-188, 2008.

Y. Tsubata, T. Okimoto, K. Miura, F. Karino, S. Iwamoto et al., Phase I clinical and pharmacokinetic study of bi-weekly carboplatin/paclitaxel chemotherapy in elderly patients with advanced non-small cell lung cancer

, Anticancer Res, vol.33, issue.1, pp.261-267, 2013.

E. Basch, B. B. Reeve, S. A. Mitchell, S. B. Clauser, L. M. Minasian et al., Development of the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE), JNCI J Natl Cancer Inst, vol.106, issue.9, p.244, 2014.

A. Anota, M. Boulin, S. Dabakuyo-yonli, P. Hillon, J. Cercueil et al., An explorative study to assess the association between health-related quality of life and the recommended phase II dose in a phase I trial: idarubicin-loaded beads for chemoembolisation of hepatocellular carcinoma, BMJ Open, vol.6, issue.6, p.10696, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01384670

F. Bonnetain, F. Fiteni, F. Efficace, and A. Anota, Statistical challenges in the analysis of health-related quality of life in Cancer clinical trials, J Clin Oncol, vol.34, issue.16, pp.1953-1959, 2016.

A. Bottomley, M. Pe, J. Sloan, E. Basch, F. Bonnetain et al., Analysing data from patient-reported outcome and quality of life endpoints for cancer clinical trials: a start in setting international standards, Lancet Oncol, vol.17, issue.11, pp.510-514, 2016.

K. D. Crew, P. Brown, H. Greenlee, T. B. Bevers, B. Arun et al., Phase IB randomized, double-blinded, placebo-controlled, dose escalation study of polyphenon E in women with hormone receptor-negative breast cancer, Cancer Prev Res, vol.5, issue.9, pp.1144-54, 2012.

Z. Xiao, J. Jia, L. Chen, W. Zou, and X. Chen, Phase I clinical trial of continuous infusion of tyroserleutide in patients with advanced hepatocellular carcinoma, Med Oncol, vol.29, issue.3, pp.1850-1858, 2012.

N. U. Lin, R. A. Freedman, N. Ramakrishna, J. Younger, A. M. Storniolo et al., A phase i study of lapatinib with whole brain radiotherapy in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer brain metastases, Breast Cancer Res Treat, vol.142, issue.2, pp.405-419, 2013.

M. Kanai, Y. Otsuka, K. Otsuka, M. Sato, T. Nishimura et al., A phase i study investigating the safety and pharmacokinetics of highly bioavailable curcumin (Theracurmin??) in cancer patients, Cancer Chemother Pharmacol, vol.71, issue.6, pp.1521-1551, 2013.

C. H. Han, P. Khwaounjoo, D. H. Kilfoyle, A. Hill, and M. J. Mckeage, Phase I druginteraction study of effects of calcium and magnesium infusions on oxaliplatin pharmacokinetics and acute neurotoxicity in colorectal cancer patients, BMC Cancer, vol.13, issue.1, p.495, 2013.

M. Rouanne, C. Massard, A. Hollebecque, V. Rousseau, A. Varga et al., Evaluation of sexuality, health-related quality-of-life and depression in advanced cancer patients: a prospective study in a phase i clinical trial unit of predominantly targeted anticancer drugs, Eur J Cancer, vol.49, issue.2, pp.431-439, 2013.

C. M. Stephenson, R. D. Levin, T. Spector, and C. G. Lis, Phase i clinical trial to evaluate the safety, tolerability, and pharmacokinetics of high-dose intravenous ascorbic acid in patients with advanced cancer, Cancer Chemother Pharmacol, vol.72, issue.1, pp.139-185, 2013.

M. K. Hunn, E. Bauer, C. E. Wood, O. Gasser, M. Dzhelali et al., Dendritic cell vaccination combined with temozolomide retreatment: results of a phase I trial in patients with recurrent glioblastoma multiforme, J Neuro-Oncol, vol.121, issue.2, pp.319-348, 2015.

K. A. Reiss, J. M. Herman, M. Zahurak, A. Brade, L. A. Dawson et al., A phase I study of Veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy in patients with advanced solid malignancies and peritoneal Carcinomatosis, Clin Cancer Res, vol.21, issue.1, pp.68-76, 2015.

M. G. Cusi, C. Botta, P. Pastina, M. G. Rossetti, E. Dreassi et al., Phase I trial of thymidylate synthase poly-epitope peptide (TSPP) vaccine in advanced cancer patients, Cancer Immunol Immunother, vol.64, issue.9, pp.1159-73, 2015.

A. J. Mcree, H. K. Sanoff, C. Carlson, A. Ivanova, O. Neil et al., A phase i trial of mFOLFOX6 combined with the oral PI3K inhibitor BKM120 in patients with advanced refractory solid tumors, Investig New Drugs, vol.33, issue.6, pp.1225-1256, 2015.

J. L. Chin, M. Billia, J. Relle, M. C. Roethke, I. V. Popeneciu et al., Magnetic resonance imaging-guided transurethral ultrasound ablation of prostate tissue in patients with localized prostate Cancer: a prospective phase 1 clinical trial, Eur Urol, vol.70, issue.3, pp.447-55, 2016.